To assess the importance of AKR1B10’s catalytic activity in PP2A assembly, we reconstituted shAKR1B10 CRC cells with AKR1B10 WT or catalytically impaired mutants: K125L, V301L (reducing catalytic activity for all-trans-retinaldehyde) (32), and C299S (targeting catalytic activity for 4-hydroxynonenal) (47). The gene discussed is AKR1B10; the disease is colorectal carcinoma.